{"id":"https://openalex.org/W3202496640","doi":"https://doi.org/10.1201/9781315151366-64","title":"Health Economics of Autoimmune Diseases Using Multiple Sclerosis as A Model","display_name":"Health Economics of Autoimmune Diseases Using Multiple Sclerosis as A Model","publication_year":2021,"publication_date":"2021-09-27","ids":{"openalex":"https://openalex.org/W3202496640","doi":"https://doi.org/10.1201/9781315151366-64","mag":"3202496640"},"language":"en","primary_location":{"id":"doi:10.1201/9781315151366-64","doi":"https://doi.org/10.1201/9781315151366-64","is_oa":false,"landing_page_url":"https://doi.org/10.1201/9781315151366-64","pdf_url":null,"source":{"id":"https://openalex.org/S4306463075","display_name":"CRC Press eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320584","host_organization_name":"CRC Press","host_organization_lineage":["https://openalex.org/P4310320584","https://openalex.org/P4310320547"],"host_organization_lineage_names":["CRC Press","Taylor & Francis"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W3201877326","display_name":"Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases"},"type":"book-chapter","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086002607","display_name":"Daniel M. Hartung","orcid":"https://orcid.org/0000-0002-0685-773X","observed_orcids":["https://orcid.org/0000-0002-0685-773X"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Daniel M. Hartung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5086002607"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.20832815,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"600","last_page":"603"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.4943999946117401,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.4943999946117401,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.40310001373291016,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.08089999854564667,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":1.0},{"id":"https://openalex.org/keywords/disease-modifying-therapy","display_name":"disease-modifying therapy","score":0.8059999942779541},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.9589999914169312},{"id":"https://openalex.org/keywords/economic-burden","display_name":"economic burden","score":0.5709999799728394},{"id":"https://openalex.org/keywords/out-of-pocket-costs","display_name":"out-of-pocket costs","score":0.7919999957084656},{"id":"https://openalex.org/keywords/health-care-expenditure","display_name":"health care expenditure","score":0.6000000238418579},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.8019999861717224},{"id":"https://openalex.org/keywords/treatment-value","display_name":"treatment value","score":0.3580000102519989}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7478649020195007},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4884037375450134},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33987897634506226}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1201/9781315151366-64","doi":"https://doi.org/10.1201/9781315151366-64","is_oa":false,"landing_page_url":"https://doi.org/10.1201/9781315151366-64","pdf_url":null,"source":{"id":"https://openalex.org/S4306463075","display_name":"CRC Press eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320584","host_organization_name":"CRC Press","host_organization_lineage":["https://openalex.org/P4310320584","https://openalex.org/P4310320547"],"host_organization_lineage_names":["CRC Press","Taylor & Francis"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8560000061988831,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3132700063","https://openalex.org/W3158062366","https://openalex.org/W7154404545","https://openalex.org/W2748489847","https://openalex.org/W2095712666","https://openalex.org/W1893735325","https://openalex.org/W2914096077","https://openalex.org/W4246928145","https://openalex.org/W7160601238","https://openalex.org/W4412638362"],"abstract_inverted_index":{"Multiple":[0],"sclerosis":[1],"(MS)":[2],"is":[3,16,61,96],"chronic":[4],"neuroinflammatory":[5],"condition":[6],"associated":[7],"with":[8],"significant":[9],"disability.":[10],"The":[11,91],"economic":[12,59],"burden":[13,70],"of":[14,32,36,93,101],"MS":[15,51,104],"also":[17],"substantial,":[18],"and":[19,21,57,85],"high":[20,75],"rising":[22],"disease-modifying":[23],"therapy":[24],"(DMT)":[25],"prices":[26],"are":[27],"the":[28,37,72,99],"single":[29],"largest":[30],"drivers":[31],"expenditures.":[33],"Over":[34],"much":[35],"last":[38],"decade,":[39],"price":[40],"increases":[41],"for":[42,71,103],"most":[43],"DMTs":[44,52],"have":[45],"surpassed":[46],"10%":[47],"annually.":[48],"Currently,":[49],"many":[50],"exceed":[53],"$90,000":[54],"a":[55,68],"year":[56],"their":[58],"value":[60],"widely":[62],"debated.":[63],"In":[64],"addition":[65],"to":[66,97],"creating":[67],"financial":[69],"healthcare":[73],"system,":[74],"DMT":[76],"costs":[77,84],"negatively":[78],"impact":[79],"patients":[80],"through":[81],"unaffordable":[82],"out-of-pocket":[83],"excessive":[86],"restrictions":[87],"by":[88],"insurance":[89],"companies.":[90],"goal":[92],"this":[94],"chapter":[95],"explore":[98],"economics":[100],"pricing":[102],"DMTs.":[105]},"counts_by_year":[],"updated_date":"2026-10-10T09:11:00.788812","created_date":"2021-10-11T00:00:00"}